Raloxifene-induced acceleration of platelet aggregation

Internal Medicine

Volumn 47, Issue 17, 2008, Pages 1523-1528

  Minamitani, Chiho ^a,c   Takai, Shinji ^b   Matsushima Nishiwaki, Rie ^b   Hanai, Yoshiteru ^a,b   Otuka, Takanobu ^c   Kozawa, Osamu ^b   Tokuda, Haruhiko ^a,b  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Akt; Osteoporosis; Platelet aggregation; Raloxifene

Indexed keywords

ADENOSINE DIPHOSPHATE; ALPHA 2 ANTIPLASMIN; PROTEIN KINASE B; RALOXIFENE;

ADULT; ARTICLE; BONE METABOLISM; BONE TURNOVER; CASE REPORT; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; LOW BACK PAIN; PATIENT REFERRAL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN FUNCTION; SIDE EFFECT; THROMBOCYTE AGGREGATION; THROMBOGENESIS; VERTEBRA FRACTURE;

BLOOD PLATELETS; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PHOSPHORYLATION; PLATELET AGGREGATION; RALOXIFENE; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 56349140137     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0732     Document Type: Article

References (20)

1. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 282: 637-645, 1999.
2. Peverill RE. Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metab 17: 149-164, 2003.
3. Born GV, Hume M. Effects of the numbers and sizes of platelet aggregates on the optical density of plasma. Nature 215: 1027-1029, 1967.
4. Cardinal DC, Flower RJ. The mudy of platelet aggregation in whole blood. Br J Pharmacol 66: 94-95, 1979.
5. Ozaki Y, Saloh K, Yalomi Y, et al. Detection of platelet aggregates with a particle counting method using light scattering. Anal Brioche 218: 284-294, 1994.
6. Tohgi H, Takahashi H, Watanabe K, Kuki H, Shirasawa Y. Development of large platelet aggregates from small aggregates as determined by laser-light scattering: effects of aggregant concentration and antiplatelet medication. Thromb Haemost 75: 838-843, 1996.
7. Haque SF, Matubayashi H, Izumi S, et al. Sex difference in platelet aggregation detected by new aggregometry using light scattering. Endocr J 48: 33-41, 2001.
8. Sakamoto T, Ogawa H, Kawano H, et al. Rapid change of platelet aggrgability in acute hyperglycemia. Detection by a novel laser-light scattering method. Thormb Haemost 83: 475-479, 2000.
9. Takei M, Matsuno H, Okada K, et al. Lack of alpha 2-antiplasnim enhances ADP induced platelet micro-aggregation through the presence of excess active plasmin in mice. J Thromb Thrombolysis 14: 205-211, 2002.
10. Matsuno H, Tokuda H, Ishisaki A, et al. P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes. J Clin Endocrinol Metab 90: 920-927. 2005.
11. Colman RW. Aggregin: a platelet ADP receptor that mediates activation. FASEB J 4: 1425-1435, 1990.
12. Kowalska MA, Ratajczak MZ, Majka M, et al. Stromal cell-derived factor-1 andmacrophage-derived chemokine: 2 factor-1 andmacrophage-derived chemokine: 2 chemokines that activate platelets. Blood 96: 50-57, 2000.
13. Fabre JE, Nguyen M, Latour A, et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 5: 1199-1202, 1999.
14. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet ageregation. J Clin Invest 113: 340-345, 2004.
15. Orimo H, Hayashi Y, Fukunaga M, et al. Osteoporosis diagnostic criteria review committee: Japanese Society for Bone and Mineral Research Diagnostic criteria for primary osteoporosis. Year 2000 version. J Bone Miner Metab 19: 331-337, 2001.
16. Nakajima K, Hirade K, Kozawa O, et al. Akt regulates thrombin-induced HSP27 phosphorylation in aortic smooth muscle cells: Function at a point downstream from p38 MAP kinase. Life Sci 77: 96-107, 2005.
17. 12 receptor-mediated platelet functional responses. Blood 104: 1335-1343, 2004.
18. Woulfe D, Jiang H, Morgans A, et al. Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J Clin Invest 113: 441-450, 2004.
19. Naik UP, Naik MU. Association of CIB with GPIIb/IIIa during outside-in signaling is required for platelet spreading on fibrinogen. Blood 102: 1335-1362, 2003.
20. Eckly A, Gendrault JL, Hechler B, et al. Differential involvement of the P2Y1 and P2YT receptors in the morphological changes of platelet aggregation. Thromb Haemost 85: 694-701, 2001.